The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
On the collegiate level, the NCAA reported $1.1 billion in revenue for the 2017 fiscal year, and college football and basketball attract large audiences, as the NCAA March Madness tournament and the College Football Playoff are some of the most watched national sporting events. In the U.S., the intercollegiate sports level serves as the main feeder system for professional and Olympic sports, with significant exceptions such as Minor League Baseball. This differs greatly from practices in nearly all other countries, where publicly and privately funded sports organizations serve this function. Eight Olympic Games have taken place in the United States, beginning with the 1904 Summer Olympics in St. Louis, Missouri. The U.S. is scheduled to host the 2028 Summer Olympics in Los Angeles and the 2034 Winter Olympics in Salt Lake City. U.S. athletes have won a total of 2,968 medals (1,179 gold) at the Olympic Games, the most of any country. In other international competition, the United States is the home of a number of prestigious events, including the America's Cup, World Baseball Classic, the U.S. Open, and the Masters Tournament. The U.S. men's national soccer team has qualified for eleven World Cups, while the women's national team has won the FIFA Women's World Cup and Olympic soccer tournament four and five times, respectively. The 1999 FIFA Women's World Cup was hosted by the United States. Its final match was attended by 90,185, setting the world record for largest women's sporting event crowd at the time.
== Autoimmune diseases == In rheumatoid arthritis and other autoimmune diseases, such as psoriatic arthritis, systemic lupus erythematosus and Sjögren's syndrome, autoantibodies often attack citrullinated proteins. The presence of anti-citrullinated protein antibody is a standard test for rheumatoid arthritis, and it is associated with more severe disease. Citrullinated proteins are also found in the cellular debris accompanying the destruction of cells in Alzheimer's disease, and after smoking cigarettes. So citrullination seems to be part of the mechanism that stimulates the immune system in autoimmune disease. However, citrullinated proteins can also be found in healthy colon mucosa.
==== 2004 DOE panel ==== In August 2003, the U.S. Secretary of Energy, Spencer Abraham, ordered the DOE to organize a second review of the field. This was thanks to an April 2003 letter sent by MIT's Peter L. Hagelstein, and the publication of many new papers, including the Italian ENEA and other researchers in the 2003 International Cold Fusion Conference, and a two-volume book by U.S. SPAWAR in 2002. Cold fusion researchers were asked to present a review document of all the evidence since the 1989 review. The report was released in 2004. The reviewers were "split approximately evenly" on whether the experiments had produced energy in the form of heat, but "most reviewers, even those who accepted the evidence for excess power production, 'stated that the effects are not repeatable, the magnitude of the effect has not increased in over a decade of work, and that many of the reported experiments were not well documented'". In summary, reviewers found that cold fusion evidence was still not convincing 15 years later, and they did not recommend a federal research program. They only recommended that agencies consider funding individual well-thought studies in specific areas where research "could be helpful in resolving some of the controversies in the field". They summarized its conclusions thus:
== Plot == Mumbai Police Commissioner Aditya Arunachalam kills gangsters in the city in police encounters. His behaviour received widespread condemnation, and the National Human Rights Commission of India decided to act against him. One of the panellists on the commission, a former friend of Aditya, discovers the murder of his daughter Valli sparked his killing spree. Past: A minister assigns Aditya to Mumbai as the new Commissioner to curb the rampant drug trafficking and prostitution in the city. Upon arriving in Mumbai, he rescues three kidnapped women, one of whom is the daughter of the Deputy Chief Minister of Maharashtra. Sensing an opportunity, Aditya uses the kidnapped women as an excuse to initiate a campaign against the city's drug trafficking and prostitution rings. His efforts are highly successful; the police arrest numerous drug dealers and child traffickers. Among the arrested is Ajay Malhotra, the son of influential industrialist Vinod Malhotra, who attempts to bail out Ajay, but Aditya refuses bail. Aditya, seeking Ajay's testimony on his involvement in drug smuggling, visits him in prison and discovers a proxy in his place. He asks the state and central governments to investigate and discovers the officials assigned to Ajay's case work for Vinod. Through a covert investigation, Aditya learns Ajay is hiding in Bangkok and has the Royal Thai Police arrest him on passport fraud charges. Corrupt diplomats on Vinod's payroll falsely declare Ajay imprisoned in India, which leads to his release from Thai custody.
Sources: en.wikipedia.org
Amino acids are polymerised via peptide bonds to form a long backbone, with the different amino acid side chains protruding along it. In biological systems, proteins are produced during translation by a cell's ribosomes. Some organisms can also make short peptides by non-ribosomal peptide synthesis, which often use amino acids other than the encoded 22, and may be cyclised, modified and cross-linked.
There are special risks to consider for older adults, and women who are pregnant. When a person ages, the body becomes less able to rid itself of barbiturates. As a result, people over the age of 65 are at higher risk of experiencing the harmful effects of barbiturates, including drug dependence and accidental overdose. When barbiturates are taken during pregnancy, the drug passes through the placenta to the fetus. After the baby is born, it may experience withdrawal symptoms and have trouble breathing. In addition, nursing mothers who take barbiturates may transmit the drug to their babies through breast milk. A rare adverse reaction to barbiturates is Stevens–Johnson syndrome, which primarily affects the mucous membranes.
Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.